Depigoid Birch 5000 Longterm Study in Adults and Adolescents

Inclusion Criteria: * Availability of an appropriately signed and dated informed consent before any study specific examination, * Clinical history of at least 2 years of seasonal allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma due to birch pollen allergy that has required repeated use of symptomatic treatment, * Patients must have a minimum level of perception of symptoms from previous seasons defined as at least a moderate symptom level (i.e. a score of 2 on the 4-point-Likert scale) in at least 2 symptom categories prior to randomization, * Lung function ≥ 80% of the predicted normal value, * IgE-mediated sensitization has to be verified by: * suggestive medical history, and * specific IgE reactivity to birch pollen (CAP-RAST ≥ 2), and * a positive SPT to birch pollen at screening or within 1 months prior to the screening visit. An SPT is considered positive if it results in a wheal diameter of at least 3.0 mm * Internet access so that patients can complete the eDiary daily via internet during all 5 pollen seasons covered by the study protocol. Exclusion Criteria: * History of significant clinical manifestations of allergy as a result of sensitization against co-allergies, particularly-but not limited to-grass or weed pollen and perennial allergens (e.g. house dust mites, cat or dog). * History of anaphylactic reaction. * Moderate or severe persistent asthma (GINA 3 or 4). * Mild persistent asthma (GINA 2), according to the Global …